MGNX Stock Forecast: MacroGenics, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$1.98
+0.51% on the day

The median 12-month analyst price target for MacroGenics, Inc. is $8.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 87 of 100 as at 18 Nov 2026 — inside the top quartile.

Market cap
$131.0M
Ticker Nerd rank
87/ 100
Median analyst target
$8.50
Analysts covering
7
Revenue$32.8M+47.6% y/y
Operating income−$13.9M
Net income$19.5M
Free cash flow−$41.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.5%
1M
−40.5%
YTD
+23.0%
1Y
+39.4%
From 52W high
−59.3%
From 52W low
+48.9%
$1.33
$4.86
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores MacroGenics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
87/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
89
Growth
86
Momentum
85
Value
72
Revisions
64
Volatility
56
Quality
52
Issuance
19

Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MGNX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MGNX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26MGNXHigh $11.00Median $8.50Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
3
Buy
4
Hold
0
Sell
$4.00
Low
$8.50
Median
$11.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026B. Riley SecuritiesMaintainsBuy$9.00 → $11
20 Apr 2026BarclaysMaintainsOverweight$4.00 → $6.00
10 Apr 2026B. Riley SecuritiesUpgradeBuy—
10 Mar 2026BarclaysMaintainsOverweight—
3 Nov 2025HC Wainwright & Co.ReiteratesNeutral—
17 Sept 2025BarclaysAssumesOverweight$3.00
15 Aug 2025Leerink PartnersMaintainsOutperform—
20 May 2025B. Riley SecuritiesMaintainsNeutral—
14 May 2025BarclaysMaintainsOverweight—
14 May 2025StifelMaintainsHold—
25 Mar 2025HC Wainwright & Co.MaintainsNeutral—
7 Nov 2024JMP SecuritiesDowngradeMarket Perform—
6 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
18 Sept 2024HC Wainwright & Co.ReiteratesNeutral—
21 Aug 2024HC Wainwright & Co.ReiteratesNeutral—
15 Aug 2024CitigroupMaintainsBuy—
7 Aug 2024BMO CapitalMaintainsMarket Perform—
1 Aug 2024BTIGDowngradeNeutral—
1 Aug 2024HC Wainwright & Co.ReiteratesNeutral—
31 July 2024B. Riley SecuritiesDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MGNX.

Market Radar

This page is one stock. Monday covers all of them.

MGNX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MGNX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, MacroGenics, Inc. returned +39.4% against +9.2% for the S&P 500, dividends included.

MGNX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300350Jan 26Apr 26Jul 26Oct 26MGNXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MGNX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.9×

Cheaper than 68% of US stocks

Price / book
5.2×

Cheaper than 18% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
54.1%

Higher than 67% of US stocks

Operating margin
−48.8%

Higher than 18% of US stocks

Net margin
—
Returns & dividend
Return on equity
−284.5%

Higher than 5% of US stocks

Return on assets
−14.6%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MacroGenics, Inc. has a market value of $131.0M.

  • Revenue in the twelve months to 30 June 2026: $167.7M. The latest quarter grew 47.6% year on year.

  • Net income over the same four quarters: −$14.6M, a −8.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$65.5M.

  • Shares outstanding: 63.6M.

  • MacroGenics, Inc. employs 293 people — $572K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

MGNX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MGNXMacroGenics, Inc.$131.0M87
ALXOALX Oncology Holdings, Inc.$125.4M40
NRXPNRX Pharmaceuticals, Inc.$124.1M19
ENGNenGene Therapeutics, Inc.$124.0M21
CDXSCodexis, Inc.$123.7M40
FATEFate Therapeutics, Inc.$122.1M85
ZNTLZentalis Pharmaceuticals, Inc.$128.8M45

Take a look at MGNX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own MacroGenics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about MGNX

What is the MGNX stock price forecast for 2026-2027?

The median 12-month analyst price target for MacroGenics, Inc. is $8.5, with estimates ranging from $4 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MGNX stock a buy right now?

Of the 7 analysts covering MacroGenics, Inc., 3 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MacroGenics, Inc. 87 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MGNX?

As at 18 Nov 2026, MacroGenics, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).

Will MGNX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts is $8.5, and Ticker Nerd's factor model ranks MacroGenics, Inc. 87 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MGNX stock forecast for 2030?

No analyst covering MacroGenics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MGNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $11 over the next 12 months.

How has MGNX stock performed over the past year?

MacroGenics, Inc. returned +39.4% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MacroGenics, Inc. do?

MacroGenics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapeutics for cancer. Its current portfolio centers on advanced biologics platforms, including antibody-drug conjugates, bispecific checkpoint antibodies, and next-generation T-cell engagers, which support a pipeline of product candidates in clinical testing.

Company

About MacroGenics, Inc.

MacroGenics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapeutics for cancer. Its current portfolio centers on advanced biologics platforms, including antibody-drug conjugates, bispecific checkpoint antibodies, and next-generation T-cell engagers, which support a pipeline of product candidates in clinical testing. The company’s work includes therapies designed to target specific tumor markers and modulate immune responses across a range of oncology settings. MacroGenics also maintains collaborations with other biotechnology and pharmaceutical companies to support development across its programs. Headquartered in Rockville, Maryland, MacroGenics plays a specialized role in the oncology market by advancing precision antibody technologies intended for use in difficult-to-treat cancers.

CEO Mr. Eric Blasius Risser · 293 employees · United States · https://www.macrogenics.com